TEM Fundamental Analysis - TEMPUS AI INC

Name: TEMPUS AI INC (TEM) Stock
Brand: TEMPUS AI INC
Rating: 4 (3 reviews)

Fundamental Rating

TEM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. TEM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TEM is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

TEM had negative earnings in the past year.

In the past year TEM has reported a negative cash flow from operations.

TEM had negative earnings in each of the past 5 years.

TEM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of TEM (-8.94%) is comparable to the rest of the industry.

TEM has a Return On Equity of -40.15%. This is in the lower half of the industry: TEM underperforms 65.52% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.94%
ROE	-40.15%
ROIC	N/A

ROA(3y)-60.21%

ROA(5y)-54.09%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TEM has a Gross Margin of 61.73%. This is amongst the best in the industry. TEM outperforms 81.03% of its industry peers.

TEM's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for TEM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	61.73%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y19.22%

GM growth 5Y16.28%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.

TEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TEM has an Altman-Z score of 3.11. This indicates that TEM is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 3.11, TEM is in the better half of the industry, outperforming 68.97% of the companies in the same industry.

TEM has a Debt/Equity ratio of 2.45. This is a high value indicating a heavy dependency on external financing.

Looking at the Debt to Equity ratio, with a value of 2.45, TEM is doing worse than 86.21% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	2.45
Debt/FCF	N/A
Altman-Z	3.11

ROIC/WACCN/A

WACC10.23%

2.3 Liquidity

A Current Ratio of 3.28 indicates that TEM has no problem at all paying its short term obligations.

TEM has a Current ratio of 3.28. This is comparable to the rest of the industry: TEM outperforms 58.62% of its industry peers.

A Quick Ratio of 3.12 indicates that TEM has no problem at all paying its short term obligations.

The Quick ratio of TEM (3.12) is better than 62.07% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.28
Quick Ratio	3.12

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TEM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.75%, which is quite impressive.

TEM shows a strong growth in Revenue. In the last year, the Revenue has grown by 72.58%.

Measured over the past years, TEM shows a very strong growth in Revenue. The Revenue has been growing by 62.05% on average per year.

EPS 1Y (TTM)85.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%56%

Revenue 1Y (TTM)72.58%

Revenue growth 3Y39.06%

Revenue growth 5Y62.05%

Sales Q2Q%84.72%

3.2 Future

The Earnings Per Share is expected to grow by 25.08% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 33.17% on average over the next years. This is a very strong growth

EPS Next Y73.5%

EPS Next 2Y40.53%

EPS Next 3Y29.06%

EPS Next 5Y25.08%

Revenue Next Year80.87%

Revenue Next 2Y49.75%

Revenue Next 3Y40.22%

Revenue Next 5Y33.17%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TEM's earnings are expected to grow with 29.06% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.53%

EPS Next 3Y29.06%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TEM does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TEMPUS AI INC

NASDAQ:TEM (11/14/2025, 9:48:10 AM)

67.37

-0.57 (-0.84%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)11-04 2025-11-04/amc

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner Change-1.05%

Ins OwnersN/A

Ins Owner Change-0.56%

Market Cap11.70B

Revenue(TTM)1.11B

Net Income(TTM)-203.88M

Analysts76.84

Price Target87.18 (29.4%)

Short Float %22.61%

Short Ratio2.48

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)22.63%

Min EPS beat(2)10.18%

Max EPS beat(2)35.09%

EPS beat(4)4

Avg EPS beat(4)18.42%

Min EPS beat(4)10.18%

Max EPS beat(4)35.09%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)2.8%

Min Revenue beat(2)0.66%

Max Revenue beat(2)4.94%

Revenue beat(4)3

Avg Revenue beat(4)1.37%

Min Revenue beat(4)-2.18%

Max Revenue beat(4)4.94%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)13.21%

PT rev (3m)25.79%

EPS NQ rev (1m)0%

EPS NQ rev (3m)1.31%

EPS NY rev (1m)2.01%

EPS NY rev (3m)1.11%

Revenue NQ rev (1m)-0.05%

Revenue NQ rev (3m)0.38%

Revenue NY rev (1m)0%

Revenue NY rev (3m)1.03%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	10.59
P/FCF	N/A
P/OCF	N/A
P/B	23.05
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.75

EYN/A

EPS(NY)-0.06

Fwd EYN/A

FCF(TTM)-1.44

FCFYN/A

OCF(TTM)-1.27

OCFYN/A

SpS6.36

BVpS2.92

TBVpS-1.9

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.94%
ROE	-40.15%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	61.73%
FCFM	N/A

ROA(3y)-60.21%

ROA(5y)-54.09%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y19.22%

GM growth 5Y16.28%

F-Score3

Asset Turnover0.48

Health

		Industry Rank	Sector Rank
Debt/Equity	2.45
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	34.04%
Cap/Sales	2.61%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.28
Quick Ratio	3.12
Altman-Z	3.11

F-Score3

WACC10.23%

ROIC/WACCN/A

Cap/Depr(3y)74.55%

Cap/Depr(5y)66.22%

Cap/Sales(3y)5.14%

Cap/Sales(5y)5.43%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)85.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%56%

EPS Next Y73.5%

EPS Next 2Y40.53%

EPS Next 3Y29.06%

EPS Next 5Y25.08%

Revenue 1Y (TTM)72.58%

Revenue growth 3Y39.06%

Revenue growth 5Y62.05%

Sales Q2Q%84.72%

Revenue Next Year80.87%

Revenue Next 2Y49.75%

Revenue Next 3Y40.22%

Revenue Next 5Y33.17%

EBIT growth 1Y65.04%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year102.24%

EBIT Next 3Y44.27%

EBIT Next 5Y36.92%

FCF growth 1Y15.18%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y11.8%

OCF growth 3YN/A

OCF growth 5YN/A

TEMPUS AI INC / TEM FAQ

What is the fundamental rating for TEM stock?

ChartMill assigns a fundamental rating of 3 / 10 to TEM.

What is the valuation status for TEM stock?

ChartMill assigns a valuation rating of 1 / 10 to TEMPUS AI INC (TEM). This can be considered as Overvalued.

What is the profitability of TEM stock?

TEMPUS AI INC (TEM) has a profitability rating of 2 / 10.

What is the expected EPS growth for TEMPUS AI INC (TEM) stock?

The Earnings per Share (EPS) of TEMPUS AI INC (TEM) is expected to grow by 73.5% in the next year.

TEMPUS AI INC (TEM) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TEMPUS AI INC / TEM FAQ

What is the fundamental rating for TEM stock?

What is the valuation status for TEM stock?

What is the profitability of TEM stock?

What is the expected EPS growth for TEMPUS AI INC (TEM) stock?